Anterogen Co

Anterogen Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anterogen Co (065660.KQ) as of Nov 9, 2026 is -2.43 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.52 B KRW — a change of -30.91% (higher).

EBITDA

-2.43 BKRW

YoY

-30.91%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anterogen Co is 2025 -2.43 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anterogen Co was 2024 -3.52 B KRW. It decreases by -30.91% higher compared to the previous year.

The Anterogen Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-2.23 B KRW
Jan 1, 2019
-4.58 B KRW
Jan 1, 2020
-2.58 B KRW
Jan 1, 2021
-2.20 B KRW
Jan 1, 2022
-5.78 B KRW
Jan 1, 2023
-5.00 B KRW
Jan 1, 2024
-3.52 B KRW
Jan 1, 2025
-2.43 B KRW
The Anterogen Co EBITDA history
YEAREBITDAYoY
-2.43 BKRW-30.91%
-3.52 BKRW-29.62%
-5.00 BKRW-13.47%
-5.78 BKRW+163.23%
-2.20 BKRW-14.90%
-2.58 BKRW-43.59%
-4.58 BKRW+104.89%
-2.23 BKRW-2,499.22%
93.09 MKRW-70.44%
314.94 MKRW+191.69%
107.97 MKRW-107.89%
-1.37 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Anterogen Co Stock analysis

What does Anterogen Co do? Anterogen Co., Ltd. generates revenue through the sale of stem cell therapy treatments and related products. The company's product portfolio includes Cupistem, used for treating Crohn’s fistula with autologous adipose-derived mesenchymal stem cells, and stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas, which serve as cosmetic raw materials to enhance skin function. Remodullins are sold for treating pulmonary arterial hypertension (PAH), while additional products provide testing services. All products are distributed within the domestic market, targeting healthcare providers and cosmetic manufacturers. The company focuses on domestic sales, with no mention of international distribution. Products like Cupistem and Remodullins are medical treatments, while SCMs, SCM2s, and Therastem-dermas cater to the cosmetic industry. The firm's revenue streams are derived from direct sales of these products to domestic customers, including hospitals, clinics, and cosmetic companies seeking advanced therapeutic and cosmetic solutions. Anterogen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Anterogen Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anterogen Co is -2.43 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anterogen Co changed from -3.52 B KRW to -2.43 B KRW, representing a -30.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Anterogen Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Anterogen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Anterogen Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Anterogen Co